Detail akcie MiMedx Grp online

Business Summary: MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, MiMedx Group Inc revenues increased 17% to $300.5M. Net income before extraordinary items decreased 3% to $33.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was offset by Selling, general and administrative expe increase of 18% to $193.1M (expense), Investigation, restatement and related decrease from $8.7M (income) to